APA (7th ed.) Citation

JP, M., Y, T., L, L., B, B., M, T., D, R., . . . LL, S. (2025). Health-related quality of life outcomes from KEYNOTE-412: Chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma. Frontiers in oncology, 15, 1645509. https://doi.org/10.3389/fonc.2025.1645509

Chicago Style (17th ed.) Citation

JP, Machiels, et al. "Health-related Quality of Life Outcomes from KEYNOTE-412: Chemoradiotherapy with or Without Pembrolizumab in Participants with Head and Neck Squamous Cell Carcinoma." Frontiers in Oncology 15 (2025): 1645509. https://doi.org/10.3389/fonc.2025.1645509.

MLA (9th ed.) Citation

JP, Machiels, et al. "Health-related Quality of Life Outcomes from KEYNOTE-412: Chemoradiotherapy with or Without Pembrolizumab in Participants with Head and Neck Squamous Cell Carcinoma." Frontiers in Oncology, vol. 15, 2025, p. 1645509, https://doi.org/10.3389/fonc.2025.1645509.